Oxford Cannabinoid
Technologies Holdings plc
("OCTP" or the
"Company")
Result of General
Meeting
Oxford Cannabinoid Technologies
Holdings plc (LSE:OCTP), the biotech company developing
prescription cannabinoid medicines, announces that the resolution
set out in the notice of General Meeting ("GM") dated 2 February 2024 was passed
at the GM held at the offices of Penningtons Manches Cooper LLP,
125 Wood Street, London EC2V 7AW on Monday 19 February
2024.
|
|
Resolution
|
For
(including discretionary)
|
%
|
Against
|
%
|
Total
|
%
of ISC voted
|
Withheld*
|
|
1.
|
To authorise the Directors to
disapply pre-emption rights
|
290,480,878
|
99.90
|
293,050
|
0.10
|
290,773,928
|
30.28
|
979,602
|
*A vote withheld is not a vote in
law and is not counted in the calculation of the proportion of
votes "For" or "Against" a resolution.
The Directors of the Company take
responsibility for this announcement.
Enquiries:
|
Oxford Cannabinoid Technologies Holdings plc
|
+44 (0)20 3034 2820
|
|
Clarissa Sowemimo-Coker
(CEO)
|
clarissa@oxcantech.com
|
|
|
|
|
Cairn Financial Advisers LLP
|
|
|
Emily Staples
|
+44 (0)20 7213 0897
|
|
Jo Turner
|
+44 (0) 20 7213 0885
|
|
|
|
|
Axis
Capital Markets Limited
|
|
|
Richard Hutchison
|
+44 (0)20 3026 0320
|
|
|
|
|
Acuitas Communications
|
020 3745 0293 / 07799
767676
|
|
Simon Nayyar
|
simon.nayyar@acuitascomms.com
|
|
Arthur Dingemans
|
arthur.dingemans@acuitascomms.com
|
About Oxford Cannabinoid Technologies Holdings
Plc:
Oxford Cannabinoid Technologies
Holdings plc ("OCTP") is the holding company of Oxford
Cannabinoid Technologies Ltd (together the "Group"), a
pharmaceutical Group developing prescription cannabinoid medicines
initially targeting the US$ multi-billion global pain
market.
OCTP currently has a portfolio of
four drug development programmes. Its lead compound, OCT461201,
will initially target neuropathic and visceral pain (including
irritable bowel syndrome ("IBS") and chemotherapy induced
peripheral neuropathy ("CIPN"). The global market for CIPN
alone is currently forecast to reach US$1.17bn by 2028.
OCTP's drug development pipeline
comprises both natural and synthetic compounds, and includes
compounds targeting trigeminal neuralgia, a severe type of face
pain, and cannabinoid derivatives targeting pain and
potentially other therapeutic areas. Having established an
exclusive licence agreement with Canopy Growth Corporation for
their entire pharmaceutical cannabinoid derivative library, OCTP
now has a portfolio of almost five hundred derivatives and
intellectual property rights including fourteen patent families and
associated research data.
OCTP has a clearly defined path to
commercialisation, revenues and growth. The Group is developing
drug candidates through clinical trials to gain regulatory approval
(FDA/MHRA/EMA) that will enable medical professionals to prescribe
them with confidence. OCTP's portfolio aims to balance risk, value
and time to market, whilst ensuring market exclusivity around all
its key activities.